BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Regeneron Pharmaceuticals readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Regeneron Pharmaceuticals's drugs
  run\, from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07477704-1033@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20261229
DTEND;VALUE=DATE:20261230
SUMMARY:Praluent (Alirocumab): Phase 2 readout est. (NCT07477704)
DESCRIPTION:Praluent (Alirocumab)\, phase 2\, Atherosclerotic Cardiovascula
 r Disease.\nStudy: A Study to See How Safe and Effective Alirocumab is Whe
 n Given Weekly to Adult Participants Who Have Hypercholesterolemia\nEstima
 ted primary completion: 29 December 2026. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/alirocumab#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT07477704
URL:https://assetmemo.bio/drug/alirocumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05608291-1975@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20270115
DTEND;VALUE=DATE:20270116
SUMMARY:Cemiplimab: Phase 3 readout est. (NCT05608291)
DESCRIPTION:Cemiplimab\, phase 3\, Melanoma.\nStudy: A Trial to See if the 
 Combination of Fianlimab With Cemiplimab Works Better Than Pembrolizumab f
 or Preventing or Delaying Melanoma From Coming Back After it Has Been Remo
 ved With Surgery\nEstimated primary completion: 15 January 2027. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/cemiplimab#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT05608291
URL:https://assetmemo.bio/drug/cemiplimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07175428-11309@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20270209
DTEND;VALUE=DATE:20270210
SUMMARY:Cenvacibart: Phase 2 readout est. (NCT07175428)
DESCRIPTION:Cenvacibart\, phase 2.\nStudy: Safety in Adult Participants Wit
 h Atrial Fibrillation Who Are Treated With Anticoagulation\nEstimated prim
 ary completion: 9 February 2027. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/cenvacibart#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT07175428
URL:https://assetmemo.bio/drug/cenvacibart#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07015905-11309@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20270220
DTEND;VALUE=DATE:20270221
SUMMARY:Cenvacibart: Phase 3 readout est. (NCT07015905)
DESCRIPTION:Cenvacibart\, phase 3\, Venous Thromboembolism.\nStudy: REGN750
 8 Versus Apixaban and Enoxaparin for Thromboprophylaxis After Total Knee A
 rthroplasty in Adults\nEstimated primary completion: 20 February 2027. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/cenvacibart#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT07015905
URL:https://assetmemo.bio/drug/cenvacibart#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06246916-1975@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20270322
DTEND;VALUE=DATE:20270323
SUMMARY:Cemiplimab: Phase 3 readout est. (NCT06246916)
DESCRIPTION:Cemiplimab\, phase 3\, Melanoma.\nStudy: A Study With Combinati
 ons of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Adva
 nced or Metastatic Melanoma (Harmony Head-to-Head)\nEstimated primary comp
 letion: 22 March 2027. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/cemiplimab#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT06246916
URL:https://assetmemo.bio/drug/cemiplimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07156500-144@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20270330
DTEND;VALUE=DATE:20270331
SUMMARY:olatorepatide: Phase 3 readout est. (NCT07156500)
DESCRIPTION:olatorepatide\, phase 3\, Type 2 Diabetes.\nStudy: A Phase 3 St
 udy of HS-20094 in Patients With T2DM Inadequately Controlled With Diet an
 d Exercise Alone\nEstimated primary completion: 30 March 2027. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/olatorepatide#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT07156500
URL:https://assetmemo.bio/drug/olatorepatide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07156539-144@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20270330
DTEND;VALUE=DATE:20270331
SUMMARY:olatorepatide: Phase 3 readout est. (NCT07156539)
DESCRIPTION:olatorepatide\, phase 3\, Type 2 Diabetes.\nStudy: A Phase 3 St
 udy of HS-20094 in Patients With T2DM\nEstimated primary completion: 30 Ma
 rch 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/olatorepati
 de#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 7156539
URL:https://assetmemo.bio/drug/olatorepatide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03564340-1975@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20270510
DTEND;VALUE=DATE:20270511
SUMMARY:Cemiplimab: Phase 1/2 readout est. (NCT03564340)
DESCRIPTION:Cemiplimab\, phase 1/2\, Ovarian Cancer.\nStudy: Study of REGN4
 018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in A
 dult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Ex
 pressing (MUC16+) Cancers\nEstimated primary completion: 10 May 2027. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/cemiplimab#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT03564340
URL:https://assetmemo.bio/drug/cemiplimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07213778-11309@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20270517
DTEND;VALUE=DATE:20270518
SUMMARY:Cenvacibart: Phase 3 readout est. (NCT07213778)
DESCRIPTION:Cenvacibart\, phase 3\, Venous Thromboembolism.\nStudy: REGN750
 8 Versus Acetylsalicylic Acid (ASA) for Venous Thromboprophylaxis After To
 tal Knee Arthroplasty in Adult Participants\nEstimated primary completion:
  17 May 2027. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/cenvaci
 bart#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T07213778
URL:https://assetmemo.bio/drug/cenvacibart#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05263206-1356@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20270602
DTEND;VALUE=DATE:20270603
SUMMARY:Dupixent (dupilumab): Phase 3 readout est. (NCT05263206)
DESCRIPTION:Dupixent (dupilumab)\, phase 3.\nStudy: Efficacy and Safety of 
 Subcutaneous Dupilumab for the Treatment of Adult Participants With Chroni
 c Pruritus of Unknown Origin (CPUO) (LIBERTY-CPUO-CHIC)\nEstimated primary
  completion: 2 June 2027. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/dupilumab#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT05263206
URL:https://assetmemo.bio/drug/dupilumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07220772-147@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20270618
DTEND;VALUE=DATE:20270619
SUMMARY:mibavademab: Phase 3 readout est. (NCT07220772)
DESCRIPTION:mibavademab\, phase 3\, Obesity.\nStudy: A Study Evaluating Mib
 avademab Treatment of Obesity Due to Leptin (LEP) Gene Mutations in Childr
 en\, Adolescents and Adults\nEstimated primary completion: 18 June 2027. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/mibavademab#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT07220772
URL:https://assetmemo.bio/drug/mibavademab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04077099-2702@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20270706
DTEND;VALUE=DATE:20270707
SUMMARY:Davutamig: Phase 1/2 readout est. (NCT04077099)
DESCRIPTION:Davutamig\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: A S
 tudy of REGN5093 in Adult Patients With Mesenchymal Epithelial Transition 
 Factor (MET)-Altered Advanced Non-Small Cell Lung Cancer\nEstimated primar
 y completion: 6 July 2027. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/davutamig#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT04077099
URL:https://assetmemo.bio/drug/davutamig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05648214-6782@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20270810
DTEND;VALUE=DATE:20270811
SUMMARY:ALN-PNP: Phase 1/2 readout est. (NCT05648214)
DESCRIPTION:ALN-PNP\, phase 1/2\, MASH / NASH.\nStudy: A Trial to Learn if 
 ALN-PNP is Safe and Well Tolerated in Healthy Adults and Adult Participant
 s With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)\nE
 stimated primary completion: 10 August 2027. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/aln-pnp#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT05648214
URL:https://assetmemo.bio/drug/aln-pnp#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06836609-6930@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20270817
DTEND;VALUE=DATE:20270818
SUMMARY:ALN-CIDEB: Phase 1/2 readout est. (NCT06836609)
DESCRIPTION:ALN-CIDEB\, phase 1/2\, MASH / NASH.\nStudy: A Study to Evaluat
 e ALN-CIDEB in Adult Participants With Metabolic Dysfunction-Associated St
 eatotic Liver Disease or With Metabolic Dysfunction-Associated Steatohepat
 itis (MASLD/MASH)\nEstimated primary completion: 17 August 2027. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/aln-cideb#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT06836609
URL:https://assetmemo.bio/drug/aln-cideb#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05785767-1975@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20270928
DTEND;VALUE=DATE:20270929
SUMMARY:Cemiplimab: Phase 2/3 readout est. (NCT05785767)
DESCRIPTION:Cemiplimab\, phase 2/3\, Non-Small Cell Lung Cancer.\nStudy: A 
 Study to Learn if a Combination of Fianlimab and Cemiplimab Versus Cemipli
 mab Alone is More Effective for Adult Participants With Advanced Non-Small
  Cell Lung Cancer (NSCLC)\nEstimated primary completion: 28 September 2027
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/cemiplimab#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT05785767
URL:https://assetmemo.bio/drug/cemiplimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06293053-1356@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20271028
DTEND;VALUE=DATE:20271029
SUMMARY:Dupixent (dupilumab): Phase 3 readout est. (NCT06293053)
DESCRIPTION:Dupixent (dupilumab)\, phase 3\, Prurigo Nodularis.\nStudy: A S
 tudy to Investigate the Pharmacokinetics and Safety of Dupilumab in Partic
 ipants ≥6 Months to <18 Years of Age With Prurigo Nodularis\nEstimated p
 rimary completion: 28 October 2027. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/dupilumab#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT06293053
URL:https://assetmemo.bio/drug/dupilumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03972657-1975@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20271115
DTEND;VALUE=DATE:20271116
SUMMARY:Cemiplimab: Phase 1/2 readout est. (NCT03972657)
DESCRIPTION:Cemiplimab\, phase 1/2\, Prostate Cancer.\nStudy: A Trial to Fi
 nd Out if REGN5678 (Nezastomig) is Safe and How Well it Works Alone or in 
 Combination With Cemiplimab for Adult Participants With Metastatic Castrat
 ion-Resistant Prostate Cancer and Other Tumors\nEstimated primary completi
 on: 15 November 2027. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /cemiplimab#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT03972657
URL:https://assetmemo.bio/drug/cemiplimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05092347-5819@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20271122
DTEND;VALUE=DATE:20271123
SUMMARY:Vonsetamig: Phase 1/2 readout est. (NCT05092347)
DESCRIPTION:Vonsetamig\, phase 1/2.\nStudy: A Study to Learn How Safe and T
 olerable Vonsetamig is in Adult Patients With Chronic Kidney Disease (CKD)
  Who Need Kidney Transplantation and Are Highly Sensitized to Human Leukoc
 yte Antigen (HLA)\nEstimated primary completion: 22 November 2027. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/vonsetamig#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT05092347
URL:https://assetmemo.bio/drug/vonsetamig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03969004-1975@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20280107
DTEND;VALUE=DATE:20280108
SUMMARY:Cemiplimab: Phase 3 readout est. (NCT03969004)
DESCRIPTION:Cemiplimab\, phase 3.\nStudy: Study of Adjuvant Cemiplimab Vers
 us Placebo After Surgery and Radiation Therapy in Patients With High Risk 
 Cutaneous Squamous Cell Carcinoma\nEstimated primary completion: 7 January
  2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/cemiplimab#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0396900
 4
URL:https://assetmemo.bio/drug/cemiplimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07685808-144@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20280121
DTEND;VALUE=DATE:20280122
SUMMARY:olatorepatide: Phase 2 readout est. (NCT07685808)
DESCRIPTION:olatorepatide\, phase 2\, Obesity.\nStudy: Study of Olatorepati
 de in Adult Participants Living With Overweight or Obesity Without Diabete
 s\nEstimated primary completion: 21 January 2028. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/olatorepatide#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT07685808
URL:https://assetmemo.bio/drug/olatorepatide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05557591-1975@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20280126
DTEND;VALUE=DATE:20280127
SUMMARY:Cemiplimab: Phase 2 readout est. (NCT05557591)
DESCRIPTION:Cemiplimab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: A Tr
 ial to Learn How the Cancer Vaccine BNT116 in Combination With Cemiplimab 
 Works and How Safe the Combination is in Adults With Advanced Non-small Ce
 ll Lung Cancer (EMPOWERVAX Lung 1)\nEstimated primary completion: 26 Janua
 ry 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/cemiplimab#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT05557
 591
URL:https://assetmemo.bio/drug/cemiplimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07235917-147@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20280128
DTEND;VALUE=DATE:20280129
SUMMARY:mibavademab: Phase 2 readout est. (NCT07235917)
DESCRIPTION:mibavademab\, phase 2.\nStudy: A Study to Investigate Mibavadem
 ab in Adult Women With Functional Hypothalamic Amenorrhea\nEstimated prima
 ry completion: 28 January 2028. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/mibavademab#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT07235917
URL:https://assetmemo.bio/drug/mibavademab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07318597-547@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20280227
DTEND;VALUE=DATE:20280228
SUMMARY:Vasigrobart: Phase 2 readout est. (NCT07318597)
DESCRIPTION:Vasigrobart\, phase 2\, Pulmonary Arterial Hypertension.\nStudy
 : Study of REGN13335 in Adult Participants With Pulmonary Arterial Hyperte
 nsion (PAH)\nEstimated primary completion: 27 February 2028. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/vasigrobart#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT07318597
URL:https://assetmemo.bio/drug/vasigrobart#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06091254-5820@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20280229
DTEND;VALUE=DATE:20280301
SUMMARY:Odronextamab: Phase 3 readout est. (NCT06091254)
DESCRIPTION:Odronextamab\, phase 3\, Follicular Lymphoma.\nStudy: A Trial t
 o Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works C
 ompared to Rituximab Combined With Different Types of Chemotherapy for Adu
 lt Participants With Previously Untreated Follicular Lymphoma\nEstimated p
 rimary completion: 29 February 2028. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/odronextamab#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT06091254
URL:https://assetmemo.bio/drug/odronextamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02991469-5897@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20280301
DTEND;VALUE=DATE:20280302
SUMMARY:Sarilumab: Phase 2 readout est. (NCT02991469)
DESCRIPTION:Sarilumab\, phase 2\, Systemic Juvenile Idiopathic Arthritis.\n
 Study: A Repeated Dose-finding Study of Sarilumab in Children and Adolesce
 nts With Systemic Juvenile Idiopathic Arthritis (SKYPS)\nEstimated primary
  completion: 1 March 2028. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/sarilumab#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT02991469
URL:https://assetmemo.bio/drug/sarilumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06091865-5820@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20280330
DTEND;VALUE=DATE:20280331
SUMMARY:Odronextamab: Phase 3 readout est. (NCT06091865)
DESCRIPTION:Odronextamab\, phase 3\, Diffuse Large B-Cell Lymphoma.\nStudy:
  A Study to Compare How Well Odronextamab Combined With Chemotherapy Works
  and How Safe it is Against Rituximab Combined With Chemotherapy\, in Adul
 t Patients With Previously Untreated Diffuse Large B-cell Lymphoma\nEstima
 ted primary completion: 30 March 2028. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/odronextamab#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT06091865
URL:https://assetmemo.bio/drug/odronextamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05519475-6912@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20280427
DTEND;VALUE=DATE:20280428
SUMMARY:Rapirosiran (ALN-HSD): Phase 2 readout est. (NCT05519475)
DESCRIPTION:Rapirosiran (ALN-HSD)\, phase 2\, MASH / NASH.\nStudy: A Precis
 ion Medicine Approach Using Gene Silencing to Treat a Chronic Liver Diseas
 e Called Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Adult 
 Participants at Increased Genetic Risk for This Condition\nEstimated prima
 ry completion: 27 April 2028. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/rapirosiran-aln-hsd#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT05519475
URL:https://assetmemo.bio/drug/rapirosiran-aln-hsd#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07919899-1356@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20280502
DTEND;VALUE=DATE:20280503
SUMMARY:Dupixent (dupilumab): Phase 3 readout est. (NCT07919899)
DESCRIPTION:Dupixent (dupilumab)\, phase 3\, Atopic Dermatitis.\nStudy: Pha
 rmacokinetics\, Immunogenicity and Safety of Subcutaneous Dupilumab and Be
 rahyaluronidase Alfa (ALT-B4) Coformulation\nEstimated primary completion:
  2 May 2028. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/dupiluma
 b#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07
 919899
URL:https://assetmemo.bio/drug/dupilumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07220785-147@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20280519
DTEND;VALUE=DATE:20280520
SUMMARY:mibavademab: Phase 3 readout est. (NCT07220785)
DESCRIPTION:mibavademab\, phase 3\, Generalized Lipodystrophy.\nStudy: Effi
 cacy and Safety of Mibavademab in Adult and Pediatric Patients With Genera
 lized Lipodystrophy\nEstimated primary completion: 19 May 2028. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/mibavademab#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT07220785
URL:https://assetmemo.bio/drug/mibavademab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06230224-5820@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20280529
DTEND;VALUE=DATE:20280530
SUMMARY:Odronextamab: Phase 3 readout est. (NCT06230224)
DESCRIPTION:Odronextamab\, phase 3\, B-Cell Non-Hodgkin Lymphoma.\nStudy: A
  Trial to Learn How Effective and Safe Odronextamab is Compared to Standar
 d of Care for Adult Participants With Previously Treated Aggressive B-cell
  Non-Hodgkin Lymphoma\nEstimated primary completion: 29 May 2028. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/odronextamab#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT06230224
URL:https://assetmemo.bio/drug/odronextamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06769698-1975@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20280604
DTEND;VALUE=DATE:20280605
SUMMARY:Cemiplimab: Phase 2 readout est. (NCT06769698)
DESCRIPTION:Cemiplimab\, phase 2.\nStudy: A Study to See if Giving Fianlima
 b and Cemiplimab Together is Better Than Cemiplimab Alone at Treating Recu
 rrent or Metastatic Head and Neck Squamous Cell Carcinoma\nEstimated prima
 ry completion: 4 June 2028. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/cemiplimab#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT06769698
URL:https://assetmemo.bio/drug/cemiplimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07112378-1356@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20280619
DTEND;VALUE=DATE:20280620
SUMMARY:Dupixent (dupilumab): Phase 3 readout est. (NCT07112378)
DESCRIPTION:Dupixent (dupilumab)\, phase 3\, Eosinophilic Esophagitis.\nStu
 dy: A Study of Dupilumab in Small Children With an Allergic Condition of t
 he Esophagus (Food Pipe): Eosinophilic Esophagitis\nEstimated primary comp
 letion: 19 June 2028. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /dupilumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT07112378
URL:https://assetmemo.bio/drug/dupilumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06787612-1975@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Cemiplimab: Phase 2 readout est. (NCT06787612)
DESCRIPTION:Cemiplimab\, phase 2\, Ovarian Cancer.\nStudy: Investigation of
  Ubamatamab Combination Therapy in Adult Participants With Platinum-Resist
 ant Ovarian Cancer\nEstimated primary completion: 30 June 2028. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/cemiplimab#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT06787612
URL:https://assetmemo.bio/drug/cemiplimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06541704-5167@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20280731
DTEND;VALUE=DATE:20280801
SUMMARY:Veopoz (Pozelimab): Phase 3 readout est. (NCT06541704)
DESCRIPTION:Veopoz (Pozelimab)\, phase 3\, Age-Related Macular Degeneration
 .\nStudy: A Study Investigating Subcutaneously Administered Pozelimab in C
 ombination With Cemdisiran or Cemdisiran Alone in Adult Participants With 
 Geographic Atrophy\nEstimated primary completion: 31 July 2028. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/pozelimab#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT06541704
URL:https://assetmemo.bio/drug/pozelimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06292780-3159@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20280820
DTEND;VALUE=DATE:20280821
SUMMARY:Linvoseltamab: Phase 1/2 readout est. (NCT06292780)
DESCRIPTION:Linvoseltamab\, phase 1/2.\nStudy: A Trial to Learn if Linvosel
 tamab is Safe and Works in Adults With Relapsed or Refractory Systemic Lig
 ht Chain Amyloidosis (AL Amyloidosis)\nEstimated primary completion: 20 Au
 gust 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/linvoselta
 mab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 06292780
URL:https://assetmemo.bio/drug/linvoseltamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05744921-5167@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20281010
DTEND;VALUE=DATE:20281011
SUMMARY:Veopoz (Pozelimab): Phase 3 readout est. (NCT05744921)
DESCRIPTION:Veopoz (Pozelimab)\, phase 3\, Paroxysmal Nocturnal Hemoglobinu
 ria.\nStudy: A Study in Adult Patients With Paroxysmal Nocturnal Hemoglobi
 nuria (PNH) to Evaluate How Safe Long-term Treatment With Pozelimab + Cemd
 isiran Combination Therapy is and How Well it Works\nEstimated primary com
 pletion: 10 October 2028. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/pozelimab#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT05744921
URL:https://assetmemo.bio/drug/pozelimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07271186-353@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20281013
DTEND;VALUE=DATE:20281014
SUMMARY:ALN-ANG3: Phase 2 readout est. (NCT07271186)
DESCRIPTION:ALN-ANG3\, phase 2\, Chronic Kidney Disease.\nStudy: Study to A
 ssess the Effects of ALN-ANG3 in Adult Participants With Diabetic Kidney D
 isease\nEstimated primary completion: 13 October 2028. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/aln-ang3#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT07271186
URL:https://assetmemo.bio/drug/aln-ang3#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07704580-5897@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20281026
DTEND;VALUE=DATE:20281027
SUMMARY:Sarilumab: Phase 1/2 readout est. (NCT07704580)
DESCRIPTION:Sarilumab\, phase 1/2\, Rheumatoid Arthritis.\nStudy: Phase 1b/
 2 Study of IV Sarilumab in Adult With RA\nEstimated primary completion: 26
  October 2028. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/sarilu
 mab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 07704580
URL:https://assetmemo.bio/drug/sarilumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04590326-1975@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20281108
DTEND;VALUE=DATE:20281109
SUMMARY:Cemiplimab: Phase 1/2 readout est. (NCT04590326)
DESCRIPTION:Cemiplimab\, phase 1/2\, Ovarian Cancer.\nStudy: A Study to Fin
 d Out How Safe REGN5668 is and How Well it Works In Adult Women When Given
  With Either Cemiplimab\, or Cemiplimab + Fianlimab\, or Ubamatamab\nEstim
 ated primary completion: 8 November 2028. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/cemiplimab#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT04590326
URL:https://assetmemo.bio/drug/cemiplimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07830329-144@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20281124
DTEND;VALUE=DATE:20281125
SUMMARY:olatorepatide: Phase 2 readout est. (NCT07830329)
DESCRIPTION:olatorepatide\, phase 2\, Obesity.\nStudy: Efficacy and Safety 
 of Olatorepatide Versus Placebo in Adults With Moderate to Severe Hidraden
 itis Suppurativa Living With Overweight or Obesity\nEstimated primary comp
 letion: 24 November 2028. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/olatorepatide#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT07830329
URL:https://assetmemo.bio/drug/olatorepatide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07896265-144@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20281219
DTEND;VALUE=DATE:20281220
SUMMARY:olatorepatide: Phase 3 readout est. (NCT07896265)
DESCRIPTION:olatorepatide\, phase 3\, Obesity.\nStudy: Efficacy And Safety 
 of Olatorepatide in Adults With Overweight or Obesity Without Diabetes\nEs
 timated primary completion: 19 December 2028. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/olatorepatide#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT07896265
URL:https://assetmemo.bio/drug/olatorepatide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06191315-1356@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20281221
DTEND;VALUE=DATE:20281222
SUMMARY:Dupixent (dupilumab): Phase 3 readout est. (NCT06191315)
DESCRIPTION:Dupixent (dupilumab)\, phase 3\, Asthma.\nStudy: Efficacy and S
 afety of Subcutaneous Dupilumab in Participants With Asthma/Asthmatic Whee
 ze Aged 2 to <6 Years (LIBERTY ASTHMA TREKIDS)\nEstimated primary completi
 on: 21 December 2028. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /dupilumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT06191315
URL:https://assetmemo.bio/drug/dupilumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07631637-6930@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20290129
DTEND;VALUE=DATE:20290130
SUMMARY:ALN-CIDEB: Phase 2 readout est. (NCT07631637)
DESCRIPTION:ALN-CIDEB\, phase 2\, MASH / NASH.\nStudy: Study to Evaluate AL
 N-CIDEB in Adults With Fibrotic Metabolic Dysfunction-Associated Steatohep
 atitis (MASH)\nEstimated primary completion: 29 January 2029. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/aln-cideb#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT07631637
URL:https://assetmemo.bio/drug/aln-cideb#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07854782-6930@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20290303
DTEND;VALUE=DATE:20290304
SUMMARY:ALN-CIDEB: Phase 3 readout est. (NCT07854782)
DESCRIPTION:ALN-CIDEB\, phase 3\, MASH / NASH.\nStudy: Trial to Evaluate AL
 N-CIDEB in Adults With Metabolic Dysfunction-Associated Steatotic Liver Di
 sease (MASLD)\nEstimated primary completion: 3 March 2029. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/aln-cideb#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT07854782
URL:https://assetmemo.bio/drug/aln-cideb#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07430956-11309@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20290328
DTEND;VALUE=DATE:20290329
SUMMARY:Cenvacibart: Phase 3 readout est. (NCT07430956)
DESCRIPTION:Cenvacibart\, phase 3.\nStudy: Stroke and Systemic Embolism Pre
 vention in Adult Participants With Atrial Fibrillation for Whom Oral Antic
 oagulation is Unsuitable\nEstimated primary completion: 28 March 2029. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/cenvacibart#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT07430956
URL:https://assetmemo.bio/drug/cenvacibart#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07933328-6930@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20290507
DTEND;VALUE=DATE:20290508
SUMMARY:ALN-CIDEB: Phase 2 readout est. (NCT07933328)
DESCRIPTION:ALN-CIDEB\, phase 2.\nStudy: Study to Evaluate ALN-CIDEB in Adu
 lts With Fibrotic Alcohol-Associated Liver Disease (ALD)\nEstimated primar
 y completion: 7 May 2029. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/aln-cideb#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT07933328
URL:https://assetmemo.bio/drug/aln-cideb#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07222761-3159@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20290521
DTEND;VALUE=DATE:20290522
SUMMARY:Linvoseltamab: Phase 3 readout est. (NCT07222761)
DESCRIPTION:Linvoseltamab\, phase 3\, Multiple Myeloma.\nStudy: A Study to 
 Compare Linvoseltamab Monotherapy and Linvoseltamab + Carfilzomib Combinat
 ion Therapy With Standard-of-Care Combination Regimens in Adult Participan
 ts With Relapsed/Refractory Multiple Myeloma (RRMM)\nEstimated primary com
 pletion: 21 May 2029. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /linvoseltamab#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT07222761
URL:https://assetmemo.bio/drug/linvoseltamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07675811-3914@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20290531
DTEND;VALUE=DATE:20290601
SUMMARY:Freneslerbart/mevonlerbart: Phase 3 readout est. (NCT07675811)
DESCRIPTION:Freneslerbart/mevonlerbart\, phase 3\, Allergic Conjunctivitis.
 \nStudy: A Study to Evaluate the Efficacy and Safety of Fel d 1 Monoclonal
  Antibodies in Adult and Pediatric Participants With Allergic Conjunctivit
 is Due to Cat Allergy\nEstimated primary completion: 31 May 2029. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/freneslerbart-mevonlerbart#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT076758
 11
URL:https://assetmemo.bio/drug/freneslerbart-mevonlerbart#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07286214-5897@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20290604
DTEND;VALUE=DATE:20290605
SUMMARY:Sarilumab: Phase 3 readout est. (NCT07286214)
DESCRIPTION:Sarilumab\, phase 3.\nStudy: Sarilumab Efficacy and Safety in A
 dults With Early Polymyalgia Rheumatica\nEstimated primary completion: 4 J
 une 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/sarilumab#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07286
 214
URL:https://assetmemo.bio/drug/sarilumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07697599-11309@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20290625
DTEND;VALUE=DATE:20290626
SUMMARY:Cenvacibart: Phase 3 readout est. (NCT07697599)
DESCRIPTION:Cenvacibart\, phase 3\, Venous Thromboembolism.\nStudy: Venous 
 Thromboembolism (VTE) Prophylaxis With REGN7508 and REGN9933 in Adult and 
 Adolescent Participants With a Peripherally Inserted Central Catheter (PIC
 C)\nEstimated primary completion: 25 June 2029. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/cenvacibart#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT07697599
URL:https://assetmemo.bio/drug/cenvacibart#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06097364-5820@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20290729
DTEND;VALUE=DATE:20290730
SUMMARY:Odronextamab: Phase 3 readout est. (NCT06097364)
DESCRIPTION:Odronextamab\, phase 3\, Follicular Lymphoma.\nStudy: A Trial t
 o Learn if Odronextamab Combined With Chemotherapy is Safe and Well-Tolera
 ted and How Well it Works Compared to Rituximab Combined With Chemotherapy
  for Adult Participants With Follicular Lymphoma\nEstimated primary comple
 tion: 29 July 2029. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/o
 dronextamab#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT06097364
URL:https://assetmemo.bio/drug/odronextamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07318610-11309@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20290818
DTEND;VALUE=DATE:20290819
SUMMARY:Cenvacibart: Phase 3 readout est. (NCT07318610)
DESCRIPTION:Cenvacibart\, phase 3.\nStudy: Reducing Adverse Vascular Outcom
 es With Factor XI Inhibition in Adult Participants With Peripheral Artery 
 Disease\nEstimated primary completion: 18 August 2029. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/cenvacibart#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT07318610
URL:https://assetmemo.bio/drug/cenvacibart#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07626411-11309@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20290911
DTEND;VALUE=DATE:20290912
SUMMARY:Cenvacibart: Phase 3 readout est. (NCT07626411)
DESCRIPTION:Cenvacibart\, phase 3.\nStudy: Stroke and Systemic Embolism Pre
 vention in Adult Participants With Atrial Fibrillation\nEstimated primary 
 completion: 11 September 2029. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/cenvacibart#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT07626411
URL:https://assetmemo.bio/drug/cenvacibart#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07675824-11303@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20290914
DTEND;VALUE=DATE:20290915
SUMMARY:REGN22530: Phase 1/2 readout est. (NCT07675824)
DESCRIPTION:REGN22530\, phase 1/2\, Glaucoma.\nStudy: REGN22530 for Adults 
 With Primary Open Angle Glaucoma or Ocular Hypertension\nEstimated primary
  completion: 14 September 2029. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/regn22530#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT07675824
URL:https://assetmemo.bio/drug/regn22530#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07887750-5820@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20291101
DTEND;VALUE=DATE:20291102
SUMMARY:Odronextamab: Phase 1/2 readout est. (NCT07887750)
DESCRIPTION:Odronextamab\, phase 1/2\, Diffuse Large B-Cell Lymphoma.\nStud
 y: REGN9220 in Combination With Odronextamab in Adult Participants With Re
 lapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphomas (BCNHLs)\nEst
 imated primary completion: 1 November 2029. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/odronextamab#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT07887750
URL:https://assetmemo.bio/drug/odronextamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07187401-11297@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20291129
DTEND;VALUE=DATE:20291130
SUMMARY:ALN-CFB: Phase 1/2 readout est. (NCT07187401)
DESCRIPTION:ALN-CFB\, phase 1/2\, Paroxysmal Nocturnal Hemoglobinuria.\nStu
 dy: A First-in-Human Safety and Efficacy Study of ALN-CFB\, a Small Interf
 ering RNA (siRNA) Targeting Complement Factor B\, in Adult Participants Wi
 th Paroxysmal Nocturnal Hemoglobinuria With Persistent Anemia on a C5 Inhi
 bitor\nEstimated primary completion: 29 November 2029. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/aln-cfb#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT07187401
URL:https://assetmemo.bio/drug/aln-cfb#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06465329-1975@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20291204
DTEND;VALUE=DATE:20291205
SUMMARY:Cemiplimab: Phase 2 readout est. (NCT06465329)
DESCRIPTION:Cemiplimab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: A St
 udy of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Pl
 us Other Cancer Treatments for Adult Patients With Operable Non-Small Cell
  Lung Cancer (NSCLC)\nEstimated primary completion: 4 December 2029. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/cemiplimab#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT06465329
URL:https://assetmemo.bio/drug/cemiplimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07876492-11309@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20291215
DTEND;VALUE=DATE:20291216
SUMMARY:Cenvacibart: Phase 3 readout est. (NCT07876492)
DESCRIPTION:Cenvacibart\, phase 3.\nStudy: A Study to Evaluate Cenvacibart 
 (REGN7508) for Secondary Stroke Prevention in Adult Participants\nEstimate
 d primary completion: 15 December 2029. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/cenvacibart#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT07876492
URL:https://assetmemo.bio/drug/cenvacibart#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05800015-1975@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20300116
DTEND;VALUE=DATE:20300117
SUMMARY:Cemiplimab: Phase 2/3 readout est. (NCT05800015)
DESCRIPTION:Cemiplimab\, phase 2/3\, Non-Small Cell Lung Cancer.\nStudy: A 
 Trial to Learn How the Combination of Fianlimab With Cemiplimab and Chemot
 herapy Works Compared With Cemiplimab and Chemotherapy for Treating Adult 
 Patients With Advanced Non-small Cell Lung Cancer\nEstimated primary compl
 etion: 16 January 2030. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/cemiplimab#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT05800015
URL:https://assetmemo.bio/drug/cemiplimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07154745-5167@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20300118
DTEND;VALUE=DATE:20300119
SUMMARY:Veopoz (Pozelimab): Phase 3 readout est. (NCT07154745)
DESCRIPTION:Veopoz (Pozelimab)\, phase 3\, Paroxysmal Nocturnal Hemoglobinu
 ria.\nStudy: A Study to Evaluate How Pozelimab + Cemdisiran Combination Th
 erapy Works in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PN
 H) Whose Current Treatment is Not Working Efficiently\nEstimated primary c
 ompletion: 18 January 2030. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/pozelimab#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT07154745
URL:https://assetmemo.bio/drug/pozelimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07410117-11309@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20300123
DTEND;VALUE=DATE:20300124
SUMMARY:Cenvacibart: Phase 3 readout est. (NCT07410117)
DESCRIPTION:Cenvacibart\, phase 3.\nStudy: REGN7508 in Adult Participants f
 or Prevention of Cancer-Associated Thrombosis\nEstimated primary completio
 n: 23 January 2030. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/c
 envacibart#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT07410117
URL:https://assetmemo.bio/drug/cenvacibart#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06413680-1975@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20300203
DTEND;VALUE=DATE:20300204
SUMMARY:Cemiplimab: Phase 1/2 readout est. (NCT06413680)
DESCRIPTION:Cemiplimab\, phase 1/2\, Melanoma.\nStudy: A First-In Human (FI
 H) Study to Find Out How Well REGN10597 Medicine Given Alone or in Combina
 tion With Cemiplimab Works in Adult Participants Who Have Cancer With Tumo
 rs That Have Spread in Their Body\nEstimated primary completion: 3 Februar
 y 2030. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/cemiplimab#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT064136
 80
URL:https://assetmemo.bio/drug/cemiplimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07527910-6782@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20300315
DTEND;VALUE=DATE:20300316
SUMMARY:ALN-PNP: Phase 2 readout est. (NCT07527910)
DESCRIPTION:ALN-PNP\, phase 2\, MASH / NASH.\nStudy: A Phase 2a Study of AL
 N-PNP With and Without a GLP1R Agonist in Adult Patients With Homozygous P
 NPLA3-Related MASLD\nEstimated primary completion: 15 March 2030. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/aln-pnp#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT07527910
URL:https://assetmemo.bio/drug/aln-pnp#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05125016-11300@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20300328
DTEND;VALUE=DATE:20300329
SUMMARY:Olsutamig: Phase 1/2 readout est. (NCT05125016)
DESCRIPTION:Olsutamig\, phase 1/2\, Prostate Cancer.\nStudy: A Trial to Fin
 d Out if REGN4336 is Safe and How Well it Works Alone and in Combination W
 ith REGN5678 for Adult Participants With Advanced Prostate Cancer\nEstimat
 ed primary completion: 28 March 2030. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/olsutamig#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT05125016
URL:https://assetmemo.bio/drug/olsutamig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06585410-1975@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20300503
DTEND;VALUE=DATE:20300504
SUMMARY:Cemiplimab: Phase 3 readout est. (NCT06585410)
DESCRIPTION:Cemiplimab\, phase 3.\nStudy: Study of Intralesional Cemiplimab
  in Adult Patients With Early Stage Cutaneous Squamous Cell Carcinoma\nEst
 imated primary completion: 3 May 2030. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/cemiplimab#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT06585410
URL:https://assetmemo.bio/drug/cemiplimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07154290-2176@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20300610
DTEND;VALUE=DATE:20300611
SUMMARY:Marlotamig: Phase 2 readout est. (NCT07154290)
DESCRIPTION:Marlotamig\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: A St
 udy to Investigate Ubamatamab With and Without Marlotamig (REGN7075) in Ad
 ult Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCL
 C)\nEstimated primary completion: 10 June 2030. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/marlotamig#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT07154290
URL:https://assetmemo.bio/drug/marlotamig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07559513-145@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20300708
DTEND;VALUE=DATE:20300709
SUMMARY:Pasatru (garetosmab): Phase 3 readout est. (NCT07559513)
DESCRIPTION:Pasatru (garetosmab)\, phase 3\, Fibrodysplasia Ossificans Prog
 ressiva.\nStudy: A Study to Investigate the Safety\, Pharmacokinetics (PK)
 \, and Efficacy of Garetosmab in Children and Adolescents With Fibrodyspla
 sia Ossificans Progressiva (FOP)\nEstimated primary completion: 8 July 203
 0. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/garetosmab#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT07559513
URL:https://assetmemo.bio/drug/garetosmab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06848088-1975@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20301009
DTEND;VALUE=DATE:20301010
SUMMARY:Cemiplimab: Phase 2 readout est. (NCT06848088)
DESCRIPTION:Cemiplimab\, phase 2\, Melanoma.\nStudy: A Study to Learn About
  the Long-Term Health of Adult Participants From a Previous Study of a New
  Melanoma Treatment\nEstimated primary completion: 9 October 2030. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/cemiplimab#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT06848088
URL:https://assetmemo.bio/drug/cemiplimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07594106-1975@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20301027
DTEND;VALUE=DATE:20301028
SUMMARY:Cemiplimab: Phase 1/2 readout est. (NCT07594106)
DESCRIPTION:Cemiplimab\, phase 1/2\, Prostate Cancer.\nStudy: REGN15505 (PS
 MAx4-1BB) Alone or in Combination With Cemiplimab or REGN4336 (PSMAxCD3) i
 n Adult Patients With Metastatic Castration-Resistant Prostate Cancer and 
 Clear Cell Renal Cell Carcinoma\nEstimated primary completion: 27 October 
 2030. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/cemiplimab#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07594106
URL:https://assetmemo.bio/drug/cemiplimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07808515-1975@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20301113
DTEND;VALUE=DATE:20301114
SUMMARY:Cemiplimab: Phase 2 readout est. (NCT07808515)
DESCRIPTION:Cemiplimab\, phase 2.\nStudy: A Study Comparing Cemiplimab-base
 d Treatments for Adult Participants With Locally Advanced Basal Cell Skin 
 Cancer (laBCC)\nEstimated primary completion: 13 November 2030. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/cemiplimab#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT07808515
URL:https://assetmemo.bio/drug/cemiplimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07832370-11296@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20310227
DTEND;VALUE=DATE:20310228
SUMMARY:ALN-6457: Phase 1/2 readout est. (NCT07832370)
DESCRIPTION:ALN-6457\, phase 1/2\, Prion Disease.\nStudy: A Trial of ALN-64
 57 in Adult Participants With Symptomatic Prion Disease (PrD)\nEstimated p
 rimary completion: 27 February 2031. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/aln-6457#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT07832370
URL:https://assetmemo.bio/drug/aln-6457#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06149286-5820@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20310430
DTEND;VALUE=DATE:20310501
SUMMARY:Odronextamab: Phase 3 readout est. (NCT06149286)
DESCRIPTION:Odronextamab\, phase 3\, Follicular Lymphoma.\nStudy: A Trial t
 o Find Out if Odronextamab Combined With Lenalidomide is Safe and Works Be
 tter Than Rituximab Combined With Lenalidomide in Adult Participants With 
 Follicular Lymphoma and Marginal Zone Lymphoma\nEstimated primary completi
 on: 30 April 2031. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/od
 ronextamab#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT06149286
URL:https://assetmemo.bio/drug/odronextamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07493304-11309@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20310718
DTEND;VALUE=DATE:20310719
SUMMARY:Cenvacibart: Phase 3 readout est. (NCT07493304)
DESCRIPTION:Cenvacibart\, phase 3\, Venous Thromboembolism.\nStudy: Treatme
 nt and Secondary Prevention of Venous Thromboembolism (VTE) in Adult Parti
 cipants With Solid and Hematologic Cancers\nEstimated primary completion: 
 18 July 2031. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/cenvaci
 bart#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T07493304
URL:https://assetmemo.bio/drug/cenvacibart#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07850921-11310@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20310728
DTEND;VALUE=DATE:20310729
SUMMARY:Nezastomig: Phase 1/2 readout est. (NCT07850921)
DESCRIPTION:Nezastomig\, phase 1/2\, Prostate Cancer.\nStudy: REGN21353 Alo
 ne or in Combination With Nezastomig for Metastatic Castration-Resistant P
 rostate Cancer in Adult Participants\nEstimated primary completion: 28 Jul
 y 2031. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/nezastomig#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT078509
 21
URL:https://assetmemo.bio/drug/nezastomig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06351592-7568@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20320321
DTEND;VALUE=DATE:20320322
SUMMARY:ALN-SOD: Phase 1/2 readout est. (NCT06351592)
DESCRIPTION:ALN-SOD\, phase 1/2\, Amyotrophic Lateral Sclerosis.\nStudy: Fi
 rst in Human (FIH) Study of ALN-SOD in Adult Participants With Amyotrophic
  Lateral Sclerosis Associated With Mutation in the SOD1 Gene (SOD1-ALS)\nE
 stimated primary completion: 21 March 2032. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/aln-sod#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT06351592
URL:https://assetmemo.bio/drug/aln-sod#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06140524-3159@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20320518
DTEND;VALUE=DATE:20320519
SUMMARY:Linvoseltamab: Phase 2 readout est. (NCT06140524)
DESCRIPTION:Linvoseltamab\, phase 2\, Multiple Myeloma.\nStudy: A Proof-of-
 Concept Study to Learn Whether Linvoseltamab Can Eliminate Abnormal Plasma
  Cells That May Lead to Multiple Myeloma in Adult Patients With High-Risk 
 Monoclonal Gammopathy of Undetermined Significance or Non-High-Risk Smolde
 ring Multiple Myeloma\nEstimated primary completion: 18 May 2032. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/linvoseltamab#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT06140524
URL:https://assetmemo.bio/drug/linvoseltamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07567469-1975@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20320827
DTEND;VALUE=DATE:20320828
SUMMARY:Cemiplimab: Phase 1/2 readout est. (NCT07567469)
DESCRIPTION:Cemiplimab\, phase 1/2.\nStudy: A Safety and Efficacy Study of 
 Combined Fianlimab + Cemiplimab in Children and Young Adults With Recurren
 t or Progressive High-Grade Glioma or Posterior Fossa-A Ependymoma\nEstima
 ted primary completion: 27 August 2032. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/cemiplimab#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT07567469
URL:https://assetmemo.bio/drug/cemiplimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05955508-3159@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20330125
DTEND;VALUE=DATE:20330126
SUMMARY:Linvoseltamab: Phase 2 readout est. (NCT05955508)
DESCRIPTION:Linvoseltamab\, phase 2\, Multiple Myeloma.\nStudy: A Proof-of-
 Concept Trial to Study the Safety and Activity of Linvoseltamab in Adult P
 articipants With Smoldering Multiple Myeloma at High Risk of Developing Mu
 ltiple Myeloma\nEstimated primary completion: 25 January 2033. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/linvoseltamab#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT05955508
URL:https://assetmemo.bio/drug/linvoseltamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03761108-3159@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20330330
DTEND;VALUE=DATE:20330331
SUMMARY:Linvoseltamab: Phase 1/2 readout est. (NCT03761108)
DESCRIPTION:Linvoseltamab\, phase 1/2\, Multiple Myeloma.\nStudy: Phase 1/2
  Study of Linvoseltamab in Adult Patients With Relapsed or Refractory Mult
 iple Myeloma\nEstimated primary completion: 30 March 2033. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/linvoseltamab#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT03761108
URL:https://assetmemo.bio/drug/linvoseltamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05730036-3159@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20330419
DTEND;VALUE=DATE:20330420
SUMMARY:Linvoseltamab: Phase 3 readout est. (NCT05730036)
DESCRIPTION:Linvoseltamab\, phase 3\, Multiple Myeloma.\nStudy: A Trial to 
 Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzum
 ab\, Pomalidomide and Dexamethasone for Adult Participants With Relapsed/R
 efractory Multiple Myeloma\nEstimated primary completion: 19 April 2033. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/linvoseltamab#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT05730036
URL:https://assetmemo.bio/drug/linvoseltamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07393282-3159@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20330727
DTEND;VALUE=DATE:20330728
SUMMARY:Linvoseltamab: Phase 3 readout est. (NCT07393282)
DESCRIPTION:Linvoseltamab\, phase 3\, Multiple Myeloma.\nStudy: A Study to 
 Compare Linvoseltamab and Daratumumab Treatment in High-Risk Smoldering Mu
 ltiple Myeloma (HR-SMM)\nEstimated primary completion: 27 July 2033. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/linvoseltamab#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT07393282
URL:https://assetmemo.bio/drug/linvoseltamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07455851-3159@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20330930
DTEND;VALUE=DATE:20331001
SUMMARY:Linvoseltamab: Phase 1/2 readout est. (NCT07455851)
DESCRIPTION:Linvoseltamab\, phase 1/2\, Multiple Myeloma.\nStudy: A Trial t
 o Study if REGN17372 in Combination With Linvoseltamab is Tolerable for Ad
 ult Participants With Relapsed/Refractory Multiple Myeloma\nEstimated prim
 ary completion: 30 September 2033. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/linvoseltamab#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT07455851
URL:https://assetmemo.bio/drug/linvoseltamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06669247-3159@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20331111
DTEND;VALUE=DATE:20331112
SUMMARY:Linvoseltamab: Phase 1/2 readout est. (NCT06669247)
DESCRIPTION:Linvoseltamab\, phase 1/2\, Multiple Myeloma.\nStudy: A Study t
 o Assess the Safety and Anti-Tumor Activity of REGN7945 in Combination Wit
 h Linvoseltamab in Adult Participants With Relapsed/Refractory Multiple My
 eloma\nEstimated primary completion: 11 November 2033. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/linvoseltamab#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT06669247
URL:https://assetmemo.bio/drug/linvoseltamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06379789-11306@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20340814
DTEND;VALUE=DATE:20340815
SUMMARY:REGV131-LNP1265: Phase 1/2 readout est. (NCT06379789)
DESCRIPTION:REGV131-LNP1265\, phase 1/2\, Hemophilia B.\nStudy: A Study to 
 Investigate the Safety and Effectiveness of a Coagulation Factor IX Gene I
 nsertion Therapy (REGV131-LNP1265) in Pediatric\, Adolescent and Adult Par
 ticipants With Hemophilia B\nEstimated primary completion: 14 August 2034.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/regv131-lnp1265#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06379789
URL:https://assetmemo.bio/drug/regv131-lnp1265#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07901725-3159@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20350725
DTEND;VALUE=DATE:20350726
SUMMARY:Linvoseltamab: Phase 3 readout est. (NCT07901725)
DESCRIPTION:Linvoseltamab\, phase 3.\nStudy: Linvoseltamab Versus Daratumum
 ab\, Bortezomib\, Cyclophosphamide\, and Dexamethasone (Dara-Vcd) in Adult
  Participants With Newly Diagnosed Systemic Light Chain Amyloidosis\nEstim
 ated primary completion: 25 July 2035. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/linvoseltamab#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT07901725
URL:https://assetmemo.bio/drug/linvoseltamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05828511-3159@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20351102
DTEND;VALUE=DATE:20351103
SUMMARY:Linvoseltamab: Phase 1/2 readout est. (NCT05828511)
DESCRIPTION:Linvoseltamab\, phase 1/2\, Multiple Myeloma.\nStudy: A Window 
 of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated\
 , and How Well it Works in Adult Participants With Recently Diagnosed Mult
 iple Myeloma Who Have Not Already Received Treatment\nEstimated primary co
 mpletion: 2 November 2035. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/linvoseltamab#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT05828511
URL:https://assetmemo.bio/drug/linvoseltamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
